Haoxi Health Technology Limited entered into a securities purchase agreement on July 10, 2026, for the sale of 300,000 Class A ordinary shares and 9,700,000 pre-funded warrants at $0.40 per share and $0.07 per warrant respectively, for gross proceeds of $4,000,000. The initial closing of the offering, which occurred on July 13, 2026, resulted in the amount of 5,100,000 Class A ordinary shares issued. The company intends to use the net proceeds for working capital, operating expenses, capital expenditures, and strategic initiatives. Haoxi Health Technology Limited is a health technology company operating in the healthcare sector.

At an extraordinary general meeting on July 6, 2026, shareholders approved a share capital reduction and reorganization. The company's authorized share capital will be reduced from US$35.2 trillion to US$11 million by reducing the par value of Class A and Class B ordinary shares from US$0.32 to US$0.0000001 per share. The resulting credit from this reduction will be transferred to a distributable reserve account to be used at the board's discretion, including to offset accumulated losses. Shareholders also approved the adoption of the ninth amended and restated memorandum and articles of association to reflect these changes. Haoxi Health Technology operates in the healthcare technology industry.

Haoxi Health Technology Limited filed a notice and proxy card regarding an upcoming Extraordinary General Meeting of shareholders. The filing includes details concerning proxy solicitation by the company, its board of directors, and executive officers. Haoxi Health Technology Limited is a health technology company based in Beijing, China.